Control
Sep 20 2022 |
et al., NCT04439006 | Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In |
| 10 patient ibrutinib late treatment RCT with results not reported over 2 years after completion. | ||
Mar 24 2022 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac104 | Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study |
| 9% higher mortality (p=1), 9% lower hospital discharge (p=1), and 35% lower progression (p=0.7). RCT 46 hospitalized patients with severe COVID-19 showing no significant differences with ibrutinib treatment. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.